Quick Answer
Immunome Inc. reported Total Assets of $683.19 million for the year ending 2025.
- Immunome Inc. showed an increase of +184.4% in Total Assets from 2024 to 2025.
- This data is from Immunome Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $11.98 million | Q1 2021: $42.59 million | Q2 2021: $64.14 million | Q3 2021: $62.56 million | Q1 2022: $47.73 million | Q2 2022: $39.02 million | Q3 2022: $30.55 million | Q1 2023: $48.11 million | Q2 2023: $41.44 million | Q3 2023: $93.16 million | Q1 2024: $319.75 million | Q2 2024: $296.22 million | Q3 2024: $256.90 million | Q1 2025: $342.69 million | Q2 2025: $296.29 million | Q3 2025: $299.38 million.
- Over the full 7 years of available data (2019 to 2025), Immunome Inc.'s Total Assets has grown by 13,401.7%.
- Historical annual values: Fiscal year 2025: $683.19 million | Fiscal year 2024: $240.24 million | Fiscal year 2023: $148.54 million | Fiscal year 2022: $24.05 million | Fiscal year 2021: $57.93 million | Fiscal year 2020: $44.53 million | Fiscal year 2019: $5.06 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: